CA 19-9 in pancreatic cancer screening

2018-04-25

Paul Moayyedi

What is the role of cancer antigen (CA) 19-9 in screening for pancreatic cancer?

Paul Moayyedi: Because pancreatic cancer mercifully is still very rare in the general population, the positive predictive value [of CA 19-9] is actually very poor. It is not a useful screening test at this stage.

Of course, as you alluded to in the last question [see Screening tests for pancreatic cancer], if we can find a biomarker that is more sensitive and specific, then perhaps that will change in the future. As of now, we would not recommend screening the general population.

See also

Surgical treatment of pancreatic pseudocysts Should the decision on surgical treatment of a pancreatic pseudocyst be based on its size (eg, diameter >5 cm) or symptoms caused by the cyst?
Systemic complications influencing survival in cirrhosis What are the most important systemic complications influencing the survival of patients with cirrhosis?
Screening tests for pancreatic cancer Is there any screening test for pancreatic cancer?
New technological advancements in the treatment of GI bleeding What are the new technological advancements in the treatment of gastrointestinal bleeding?
Heterogeneity in the population of patients with cancer of unknown primary Is the population of patients with cancer of unknown primary heterogeneous? What malignancies dominate in this group?
Changing approaches to inflammatory bowel disease management A lecture by Prof. John Marshall, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
Celiac disease and other forms of gluten intolerance in adults A lecture by Prof. Paul Moayyedi, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.

CA 19-9 in pancreatic cancer screening

Social Media